title: A tale of two factors: what determines the rate of progression in Huntington's disease? A longitudinal MRI study.
abstract: Over the past several years, increased attention has been devoted to understanding regionally selective brain changes that occur in Huntington's disease and their relationships to phenotypic variability. Clinical progression is also heterogeneous, and although CAG repeat length influences age of onset, its role, if any, in progression has been less clear. We evaluated progression in Huntington's disease using a novel longitudinal magnetic resonance imaging analysis. Our hypothesis was that the rate of brain atrophy is influenced by the age of onset of Huntington's disease. We scanned 22 patients with Huntington's disease at approximately 1-year intervals; individuals were divided into 1 of 3 groups, determined by the relative age of onset. We found significant differences in the rates of atrophy of cortex, white matter, and subcortical structures; patients who developed symptoms earlier demonstrated the most rapid rates of atrophy compared with those who developed symptoms during middle age or more advanced age. Rates of cortical atrophy were topologically variable, with the most rapid changes occurring in sensorimotor, posterior frontal, and portions of the parietal cortex. There were no significant differences in the rates of atrophy in basal ganglia structures. Although both CAG repeat length and age influenced the rate of change in some regions, there was no significant correlation in many regions. Rates of regional brain atrophy seem to be influenced by the age of onset of Huntington's disease symptoms and are only partially explained by CAG repeat length. These findings suggest that other genetic, epigenetic, and environmental factors play important roles in neurodegeneration in Huntington's disease.
authors: Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts, USA. rosas@helix.mgh.harvard.edu
authors: H Diana
authors: HD
authors: Rosas
authors: Martin
authors: M
authors: Reuter
authors: Gheorghe
authors: G
authors: Doros
authors: Stephanie Y
authors: SY
authors: Lee
authors: Tyler
authors: T
authors: Triggs
authors: Keith
authors: K
authors: Malarick
authors: Bruce
authors: B
authors: Fischl
authors: David H
authors: DH
authors: Salat
authors: Steven M
authors: SM
authors: Hersch
references: J Neurol. 2009 Feb;256(2):203-12
references: 19266143
references: Neurogenetics. 2004 Feb;5(1):9-17
references: 14745585
references: Mov Disord. 2008 Jul 15;23(9):1223-7
references: 18512767
references: J Neurosci. 2009 Dec 2;29(48):15223-31
references: 19955375
references: Neuroimage. 2006 Jul 1;31(3):968-80
references: 16530430
references: Nature. 2007 May 24;447(7143):447-52
references: 17450122
references: Neuron. 2002 Jan 31;33(3):341-55
references: 11832223
references: Cereb Cortex. 2004 Jul;14(7):721-30
references: 15054051
references: J Nucl Med. 2001 Nov;42(11):1591-5
references: 11696626
references: Neurosci Lett. 1999 Sep 3;272(1):53-6
references: 10507541
references: Brain. 2010 Apr;133(Pt 4):1094-110
references: 20375136
references: J Med Genet. 1994 Nov;31(11):872-4
references: 7853373
references: Mov Disord. 1996 Mar;11(2):136-42
references: 8684382
references: Neurology. 1998 May;50(5):1357-65
references: 9595987
references: Brain. 2008 Apr;131(Pt 4):1057-68
references: 18337273
references: Neurology. 2006 Apr 11;66(7):1016-20
references: 16606912
references: Neuroimage. 2006 Aug 1;32(1):180-94
references: 16651008
references: Neuroimage. 2010 Dec;53(4):1181-96
references: 20637289
references: IEEE Trans Med Imaging. 2001 Jan;20(1):70-80
references: 11293693
references: Neurology. 1997 Feb;48(2):394-9
references: 9040728
references: Neurology. 2000 Jan 25;54(2):452-8
references: 10668713
references: Prog Neurobiol. 2007 Nov;83(4):228-48
references: 17467140
references: Neuroimage. 2010 Feb 15;49(4):2995-3004
references: 19850138
references: Neurology. 1995 Oct;45(10):1879-83
references: 7477986